Table 1.

Clinical trials for first-line treatment of advanced HCC.

Study Name	Design	Met Primary Endpoint(s)	Patients (n)	TTP/PFS (Months)	mOS (Months)
1st Line Setting
SHARP	Sorafenib vs. placebo	Yes	Sorafenib (299) Placebo (303)	5.5 vs. 2.8 HR = 0.58 95% CI: 0.45–0.74 p < 0.001	10.7 vs. 7.9 HR = 0.69 95% CI: 0.55–0.87 p < 0.001
Asian-Pacific	Sorafenib vs. placebo	Yes	Sorafenib (150) Placebo (76)	2.8 vs. 1.4 HR = 0.57 95% CI: 0.42–0.79 p < 0.001	6.5 vs. 4.2 HR = 0.68 95% CI: 0.50–0.93 p = 0.014
SUN1170	Sunitinib vs. sorafenib	No	Sunitinib (530) Sorafenib (544)	4.1 vs. 3.8 HR = 1.13 95% CI: 0.98–1.31 p = 0.308	7.9 vs. 10.2 HR = 1.30 95% CI: 1.13–1.50 p = 0.001
BRISK-FL	Brivanib vs. sorafenib	No	Brivanib (577) Sorafenib (578)	4.2 vs. 4.1 HR = 1.01 95% CI: 0.88–1.16 p = 0.853	9.5 vs. 9.9 HR = 1.06 95% CI: 0.93–1.22 p = 0.373
LIGHT	Linifanib vs. sorafenib	No	Linifanib (514) Sorafenib (521)	5.4 vs. 4.0 HR = 0.76 95% CI: 0.64–0.90 p = 0.001	9.1 vs. 9.8 HR = 1.04 95% CI: 0.90–1.22 p = NS
SEARCH	Sorafenib +/− erlotinib	No	Sorafenib + Erlotinib (362) Sorafenib + placebo (358)	3.2 vs. 4.0 HR = 1.135 95% CI: 0.94–1.37 p = 0.180	9.5 vs. 8.5 HR = 0.929 95% CI: 0.78–1.11 p = 0.408
CALGB80802	Sorafenib +/− doxorubicin	No	Sorafenib + Doxorubicin (180) Sorafenib + Placebo (176)	3.6 vs. 3.2 * HR = 0.90 95% CI: 0.72–1.20 p = NS	9.3 vs. 10.5 HR = 1.06 95% CI: 0.80–1.40 p = NS
REFLECT	Lenvatinib vs. sorafenib	Yes	Lenvatinib (478) Sorafenib (476)	8.9 vs. 3.7 HR = 0.63 95% CI: 0.53–0.73 p < 0.0001	13.6 vs. 12.3 HR = 0.92 95% CI: 0.79–1.06 p = NS
SARAH	Y90 vs. sorafenib	No	Y90 (237) Sorafenib (222)	4.1 vs. 3.7 * HR = 1.03 95% CI: 0.85–1.25 p = 0.760	8.0 vs. 9.9 HR = 1.15 95% CI: 0.94–1.14 p = 0.180
SIRveNIB	Y90 vs. sorafenib	No	Y90 (182) Sorafenib (178)	6.1 vs. 5.4 HR = 0.88 95% CI: 0.70–1.10 p = 0.290	8.8 vs. 10.0 HR = 1.10 95% CI: 0.90–1.40 p = 0.360

* Progression-Free Survival (PFS); NS: not significant.